Eye Journal

Overview
Identity
View All

publication venue for

AUTOMATED SEGMENTATION OF HYPERREFLECTIVE FOCI IN DMO SHOWS GREATER VOLUME REDUCTION WITH FARICIMAB VS AFLIBERCEPT IN THE PHASE 3 YOSEMITE AND RHINE TRIALS 2024
EFFICACY AND SAFETY OF FARICIMAB IN ALTIMETER: A TRIAL EXPLORING BIOMARKERS OF ANG-2 INHIBITION IN PATIENTS WITH DMO 2024
FARICIMAB REDUCES MACULAR LEAKAGE VS AFLIBERCEPT IN PATIENTS WITH DMO 2024
IMPACT OF FARICIMAB VS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN EYES WITH DMO IN THE YOSEMITE/RHINE PHASE 3 TRIALS 2024
REAL-WORLD VOYAGER STUDY OF FARICIMAB IN NAMD AND DMO: BASELINE AND 3-MONTH DATA 2024
Internal limiting membrane peel size and macular hole surgery outcome: a systematic review and individual participant data study of randomized controlled trials.. 39:1406-1413. 2025
Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration.. 39:860-869. 2025
Risk assessment models: considerations prior to use in clinical practice.. 39:617-619. 2025
INFOGRAPHIC: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from YOSEMITE and RHINE).. 39:167-169. 2025
Pilot and feasibility studies in ophthalmology: fundamental keys to success.. 39:4-6. 2025
Exploring the fragility of meta-analyses in ophthalmology: a systematic review. 38:3153-3160. 2024
Global estimates on the number of people blind or visually impaired by Uncorrected Refractive Error: a meta-analysis from 2000 to 2020. 38:2083-2101. 2024
Global estimates on the number of people blind or visually impaired by age-related macular degeneration: a meta-analysis from 2000 to 2020. 38:2070-2082. 2024
Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020. 38:2156-2172. 2024
Global estimates on the number of people blind or visually impaired by glaucoma: A meta-analysis from 2000 to 2020. 38:2036-2046. 2024
Publisher Correction: Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020. 38:2229-2231. 2024
Correction: Retinal non-perfusion: recognizing and defining what is important. 38:1782-1782. 2024
Retinal non-perfusion: recognizing and defining what is important. 38:1608-1609. 2024
The ophthalmologist’s guide to evaluating the certainty of evidence using the GRADE approach. 38:1601-1604. 2024
Correction: The 5 min meta-analysis: understanding how to read and interpret a forest plot. 37:3704-3704. 2023
Deep phenotypic characterization of the retinal dystrophy in patients with RNU4ATAC-associated Roifman syndrome. 37:3734-3742. 2023
What makes a good survey?. 37:3299-3301. 2023
Interpreting results from randomized controlled trials: What measures to focus on in clinical practice. 37:3055-3058. 2023
Noninferiority randomised trials in ophthalmology. 37:3059-3060. 2023
The need for a pragmatic, individualized treat-and-extend (T&E) treatment paradigm for centre-involving diabetic macular oedema. 37:2431-2433. 2023
Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials. 37:1966-1974. 2023
Correction to: Risk of bias: why measure it, and how?. 37:1516-1516. 2023
Correction to: The clinician’s guide to p values, confidence intervals, and magnitude of effects. 37:1515-1515. 2023
Treat & extend in neovascular age-related macular degeneration: how we got here and where do we go next?. 37:581-583. 2023
Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. 37:6-16. 2023
Sensitivity analysis in clinical trials: three criteria for a valid sensitivity analysis. 36:2073-2074. 2022
When to believe a subgroup analysis: revisiting the 11 criteria. 36:2075-2077. 2022
The clinician’s guide to interpreting a regression analysis. 36:1715-1717. 2022
A clinician’s guide to network meta-analysis. 36:1523-1526. 2022
Measuring atrophy in age-related macular degeneration: why does reliability matter?. 36:1527-1528. 2022
Seeing the patient’s perspective: a guide to patient-reported outcome measures and minimal important differences in ophthalmic research. 36:1339-1341. 2022
Guidelines for patient management: considerations before adoption into practice. 36:1135-1137. 2022
Cohort studies investigating the effects of exposures: key principles that impact the credibility of the results. 36:905-906. 2022
The 5 min meta-analysis: understanding how to read and interpret a forest plot. 36:673-675. 2022
The clinician’s guide to randomized trials: interpretation. 36:481-482. 2022
Risk of bias: why measure it, and how?. 36:346-348. 2022
The clinician’s guide to p values, confidence intervals, and magnitude of effects. 36:341-342. 2022
Ophthalmic image acquired by ophthalmologists and by allied health personnel as part of a telemedicine strategy: a comparative study of image quality. 35:1398-1404. 2021
Myopia prevalence in Canadian school children: a pilot study. 32:1042-1047. 2018
Elbow splinting as a method to increase patching compliance in amblyopia therapy. 31:406-410. 2017
A prospective outcome study of membranous and solid distal common canalicular obstructions. 30:621-626. 2016
Indentation and needle insertion properties of the human eye. 28:880-887. 2014
Response to Tatham and Brookes. 27:109-110. 2013
BEST1-related autosomal dominant vitreoretinochoroidopathy: a degenerative disease with a range of developmental ocular anomalies. 25:113-118. 2011
National survey of corneal abrasion treatment. 12:278-281. 1998
The use of contact lenses to correct aphakia in a clinical trial of cataract management. 4:138-144. 1990
Subjective assessment of the effect of cataract surgery and a review of long term aims. 1:247-253. 1987
SUBJECTIVE ASSESSMENT OF THE EFFECT OF CATARACT-SURGERY AND A REVIEW OF LONG-TERM AIMS. 1:247-253. 1987

has subject area

1103 Clinical Sciences (FoR)
1107 Immunology (FoR)
1113 Opthalmology and Optometry (FoR)
Ophthalmology & Optometry (Science Metrix)